A Phase 1 Trial of Oncolytic HSV-1, G207, Given in Combination With Radiation for Recurrent GBM Demonstrates Safety and Radiographic Responses

G207, a mutant herpes simplex virus (HSV) type 1, is safe when inoculated into recurrent malignant glioma. We conducted a phase 1 trial of G207 to demonstrate the safety of stereotactic intratumoral administration when given 24 hours prior to a single 5 Gy radiation dose in patients with recurrent m...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Markert, James M, Razdan, Shantanu N, Kuo, Hui-Chien, Cantor, Alan, Knoll, Anette, Karrasch, Matthias, Nabors, L Burt, Markiewicz, Michael, Agee, Bonita S, Coleman, Jennifer M, Lakeman, Alfred D, Palmer, Cheryl A, Parker, Jacqueline N, Whitley, Richard J, Weichselbaum, Ralph R, Fiveash, John B, Gillespie, G Yancey
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2014
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4015243/
https://ncbi.nlm.nih.gov/pubmed/24572293
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mt.2014.22
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller